Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Stereotaxis ( (STXS) ) has shared an update.
On April 14, 2026, Stereotaxis agreed to acquire 100% of French robotic cardiology innovator Robocath in a deal expected to close in July 2026, subject to debt restructuring, French regulatory clearance, and other customary conditions. The upfront consideration is valued at $20 million in cash, Stereotaxis stock priced at $2.00 per share, or a mix of both, adjusted for Robocath’s debt, working capital, interim financing, and certain risk-related costs.
The agreement includes up to $25 million in additional earnout payments tied to U.S. FDA approval and specified commercial sales milestones for Robocath’s next-generation devices, deliverable in cash, stock, or a combination, within an issuance limit of 19.9% of Stereotaxis’ pre-closing shares. Stereotaxis will also provide interim monthly bond financing to Robocath of about €1.3 million initially, while both sides are bound by customary covenants, termination rights through December 31, 2026, and a termination fee framework that underscores the strategic importance of the transaction for both parties.
The most recent analyst rating on (STXS) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Stereotaxis stock, see the STXS Stock Forecast page.
Spark’s Take on STXS Stock
According to Spark, TipRanks’ AI Analyst, STXS is a Neutral.
The score is held down primarily by persistent losses and ongoing negative free cash flow, alongside a technically weak price trend below key moving averages. Offsetting these risks, the latest earnings call provided constructive 2026 growth guidance and detailed ramp plans tied to regulatory wins, while valuation is difficult to support given a negative P/E and no stated dividend yield.
To see Spark’s full report on STXS stock, click here.
More about Stereotaxis
Stereotaxis, Inc. operates in the medical technology industry, focusing on robotic systems and related technologies for interventional cardiology and neurointerventions. By acquiring Robocath, a Rouen, France-based venture-backed developer of advanced mechanical robotic platforms for these procedures, Stereotaxis aims to expand its portfolio of next-generation interventional medical devices and strengthen its position in image-guided, catheter-based therapies.
Average Trading Volume: 445,599
Technical Sentiment Signal: Sell
Current Market Cap: $186.7M
For detailed information about STXS stock, go to TipRanks’ Stock Analysis page.